Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383–96. https://doi.org/10.1016/S0140-6736(17)31462-9.

Article  PubMed  Google Scholar 

Cancer Genome Atlas Research Network; Analysis Working Group: Asan University; BC Cancer Agency. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–75. https://doi.org/10.1038/nature20805.

Article  CAS  Google Scholar 

Lewis S, Lukovic J. Neoadjuvant therapy in esophageal cancer. Thorac Surg Clin. 2022;32:447–56. https://doi.org/10.1016/j.thorsurg.2022.06.003.

Article  PubMed  Google Scholar 

Shi R, Radulovich N, Ng C, et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res. 2019;26(5):1162–74.

Article  PubMed  Google Scholar 

Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49:1567–75. https://doi.org/10.1038/ng.3967.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69:3364–73. https://doi.org/10.1158/0008-5472.CAN-08-4210.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5. https://doi.org/10.1038/nature07935.

Article  CAS  PubMed  Google Scholar 

Kijima T, Nakagawa H, Shimonosono M, et al. Three-dimensional organoids reveal therapy resistance of esophageal and oropharyngeal squamous cell carcinoma cells. Cell Mol Gastroenterol Hepatol. 2019;7:73–91. https://doi.org/10.1016/j.jcmgh.2018.09.003.eCollection9.

Article  PubMed  Google Scholar 

Li X, Francies HE, Secrier M, et al. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. Nat Commun. 2018;9:2983. https://doi.org/10.1038/s41467-018-05190-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yokota E, Iwai M, Yukawa T, et al. Clinical application of a lung cancer organoid (tumoroid) culture system. NPJ Precis Oncol. 2021;5:29. https://doi.org/10.1038/s41698-021-00166-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fukazawa T, Guo M, Ishida N, et al. SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. Sci Rep. 2016;6:20113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou XP, Sanson M, Hoang-Xuan K, et al. Germline mutations of p53 but not p16/CDKN2 or PTEN/MMAC1 tumor suppressor genes predispose to gliomas: the ANOCEF Group—Association des NeuroOncologues d’Expression Française. Ann Neurol. 1999;46:913–6. https://doi.org/10.1002/531-8249(199912)46:6%3c913::aid-ana15%3e3.0.co;2-x.

Article  CAS  PubMed  Google Scholar 

Kotler E, Shani O, Goldfeld G, et al. A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation. Mol Cell. 2018;71:178-90.e8. https://doi.org/10.1016/j.molcel.2018.06.012.

Article  CAS  PubMed  Google Scholar 

Kilroy MK, Park S, Feroz W, et al. HER3 alterations in cancer and potential clinical implications. Cancers (Basel). 2022;14:6174. https://doi.org/10.3390/cancers14246174.

Article  CAS  PubMed  Google Scholar 

Zhang T, Febres-Aldana CA, Liu Z, et al. HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor. Clin Cancer Res. 2024;30:4701–13. https://doi.org/10.1158/078-0432.CCR-24-1835.

Article  CAS  PubMed  Google Scholar 

King DA, Smith AR, Pineda G, et al. Complete remission of widely metastatic human epidermal growth factor receptor 2-amplified pancreatic adenocarcinoma after precision immune and targeted therapy with description of sequencing and organoid correlates. JCO Precis Oncol. 2023;7: e2100489. https://doi.org/10.1200/PO.21.00489.

Article  PubMed  PubMed Central  Google Scholar 

Yokota E, Iwai M, Yukawa T, et al. Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies. Cancer Lett. 2024;588: 216816. https://doi.org/10.1016/j.canlet.2024.216816.

Article  CAS  PubMed  Google Scholar 

Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30. https://doi.org/10.1056/NEJMoa2004413.

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744–56. https://doi.org/10.1016/S470-2045(23)00215-2.

Article  PubMed  PubMed Central  Google Scholar 

Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.

Article  CAS  PubMed  Google Scholar 

Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst. 2013;105:266–73. https://doi.org/10.1093/jnci/djs501.

Article  CAS  PubMed  Google Scholar 

LoRusso P, Jänne PA, Oliveira M, et al. Phase I study of U3–1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2013;19:3078–87. https://doi.org/10.1158/078-0432.CCR-12-3051.

Article  CAS  PubMed  Google Scholar 

Krop IE, Masuda N, Mukohara T, et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter phase I/II trial. J Clin Oncol. 2023;41:5550–60. https://doi.org/10.1200/JCO.23.00882.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu HA, Baik C, Kim DW, et al. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Ann Oncol. 2024;35:437–47. https://doi.org/10.1016/j.annonc.2024.02.003.

Article  CAS  PubMed  Google Scholar 

Begnami MD, Fukuda E, Fregnani JH, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol. 2011;29:3030–6. https://doi.org/10.1200/JCO.2010.33.6313.

Article  CAS  PubMed  Google Scholar 

Hayashi M, Inokuchi M, Takagi Y, et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008;14:7843–9. https://doi.org/10.1158/078-0432.CCR-08-1064.

Article  CAS  PubMed  Google Scholar 

Ecker BL, Taylor L, Zhang PJ, et al. HER3 expression is a marker of tumor progression in premalignant lesions of the gastroesophageal junction. PLoS ONE. 2016;11: e0161781. https://doi.org/10.1371/journal.pone.

Article